WO2014123930A3 - Prévention et traitement de fibrose de tissu - Google Patents

Prévention et traitement de fibrose de tissu Download PDF

Info

Publication number
WO2014123930A3
WO2014123930A3 PCT/US2014/014733 US2014014733W WO2014123930A3 WO 2014123930 A3 WO2014123930 A3 WO 2014123930A3 US 2014014733 W US2014014733 W US 2014014733W WO 2014123930 A3 WO2014123930 A3 WO 2014123930A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
stem cells
tissue fibrosis
prevention
surgical adhesions
Prior art date
Application number
PCT/US2014/014733
Other languages
English (en)
Other versions
WO2014123930A2 (fr
Inventor
Joseph L. Williams
Paul A. Lucas
Brian S. Murphy
Original Assignee
Williams Joseph L
Lucas Paul A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Williams Joseph L, Lucas Paul A filed Critical Williams Joseph L
Publication of WO2014123930A2 publication Critical patent/WO2014123930A2/fr
Publication of WO2014123930A3 publication Critical patent/WO2014123930A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des procédés de prévention de développement et/ou de traitement d'une fibrose de tissu provoquée, par exemple, par des adhérences chirurgicales au moyen de l'administration de cellules souches et de cellules souches en combinaison avec des matrices ou d'autres molécules, ou des produits dérivés de celles-ci. Dans un mode de réalisation, des cellules souches pluripotentes sont disposées par voie intrapéritonéale seules, ou fixées à une matrice ou incorporées dans celle-ci. Diverses combinaisons de cellules, de produits de celles-ci et de facteurs de régénération sont capables de réduire la formation d'adhérences chirurgicales à la fois prophylactiquement et thérapeutiquement.
PCT/US2014/014733 2013-02-05 2014-02-04 Prévention et traitement de fibrose de tissu WO2014123930A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361760847P 2013-02-05 2013-02-05
US61/760,847 2013-02-05

Publications (2)

Publication Number Publication Date
WO2014123930A2 WO2014123930A2 (fr) 2014-08-14
WO2014123930A3 true WO2014123930A3 (fr) 2015-02-26

Family

ID=51300245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/014733 WO2014123930A2 (fr) 2013-02-05 2014-02-04 Prévention et traitement de fibrose de tissu

Country Status (1)

Country Link
WO (1) WO2014123930A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105018428A (zh) * 2015-05-27 2015-11-04 贵州北科泛特尔生物科技有限公司 脐带血造血干细胞的体外扩增方法
CN105670987B (zh) * 2016-03-21 2019-04-02 杭州市萧山区中医院 一种毛囊干细胞诱导分化为血管内皮细胞的抑制方法
JPWO2018003997A1 (ja) * 2016-07-01 2019-04-25 国立大学法人東北大学 臓器線維症の予防または治療剤
CN108441474B (zh) * 2018-03-23 2021-10-08 天晴干细胞股份有限公司 一种来源于脐带血、胎盘造血干细胞分离纯化的方法
CN109364090B (zh) * 2018-12-06 2020-10-23 西华大学 油橄榄叶提取物在制备防治胎儿酒精综合症药物中的应用
AU2020207410A1 (en) * 2019-01-11 2021-08-19 Figene, Llc Fibroblast regenerative cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260751A1 (en) * 2004-05-20 2005-11-24 New York Medical College Pluripotent adult stem cells
US20080159998A1 (en) * 2006-12-18 2008-07-03 Medistem Labortories Stem cell mediated treg activation/expansion for therapeutic immune modulation
US20100167260A1 (en) * 2006-01-19 2010-07-01 Medestea Research & Production Spa Use of N-Piperidine Derivative Compositions for Protecting Biological Systems
US20100261152A1 (en) * 2005-02-15 2010-10-14 Medistem Laboratories, Inc. Method for expansion of stem cells
EP2333049A1 (fr) * 1999-09-24 2011-06-15 ABT Holding Company Cellules souches pluripotentes de type embryonnaires, leurs compositions, procédés et utilisations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2333049A1 (fr) * 1999-09-24 2011-06-15 ABT Holding Company Cellules souches pluripotentes de type embryonnaires, leurs compositions, procédés et utilisations
US20050260751A1 (en) * 2004-05-20 2005-11-24 New York Medical College Pluripotent adult stem cells
US20100261152A1 (en) * 2005-02-15 2010-10-14 Medistem Laboratories, Inc. Method for expansion of stem cells
US20100167260A1 (en) * 2006-01-19 2010-07-01 Medestea Research & Production Spa Use of N-Piperidine Derivative Compositions for Protecting Biological Systems
US20080159998A1 (en) * 2006-12-18 2008-07-03 Medistem Labortories Stem cell mediated treg activation/expansion for therapeutic immune modulation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AZARI, H ET AL.: "Isolation And Expansion Of The Adult Mouse Neural Stem Cells Using The Neurosphere Assay.", JOVE, vol. 45, 2010, pages 1 - 4, Retrieved from the Internet <URL:http://www.jove.com/details.php?id=2393;> *
GENTILE, P ET AL.: "Concise Review: Adipose-Derived Stromal Vascular Fraction Cells And Platelet-Rich Plasma: Basic And Clinical Implications For Tissue Engineering Therapies In Regenerative Surgery.", STEM CELLS TRANSLATIONAL MEDICINE, vol. 1, 22 February 2012 (2012-02-22), pages 230 - 236 *
MCELROY, SL ET AL.: "Noninvasive Human Nuclear Transfer with Embryonic Stem Cells.", COLD SPRING HARBOR PROTOCOLS., vol. 3, no. 9, September 2008 (2008-09-01), pages 1 - 5 *
MENG, X ET AL.: "Endometrial Regenerative Cells: A Novel Stem Cell Population.", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 5, no. 57, 15 November 2007 (2007-11-15), pages 1 - 10 *
PARK, TS ET AL., GROWTH FACTOR-ACTIVATED STEM CELL CIRCUITS AND STROMAL SIGNALS COOPERATIVELY ACCELERATE NON-INTEGRATED IPSC REPROGRAMMING OF HUMAN MYELOID PROGENITORS., vol. 7, no. 8, August 2012 (2012-08-01), pages 1 - 22 *
RIA, R ET AL.: "Induction Therapy And Stem Cell Mobilization In Patients With Newly Diagnosed Multiple Myeloma.", vol. 2012, 2012, pages 1 - 7 *
SHAH, SN ET AL.: "HMGA1 Reprograms Somatic Cells Into Pluripotent Stem Cells By Inducing Stem Cell Transcriptional Networks.", PLOS ONE., vol. 7, no. 11, November 2012 (2012-11-01), pages 1 - 10 *
WANG, N ET AL.: "Mesenchymal Stem Cells Attenuate Peritoneal Injury Through Secretion Of TSG- 6.", PLOS ONE., vol. 7, no. 8, August 2012 (2012-08-01), pages 1 - 17 *

Also Published As

Publication number Publication date
WO2014123930A2 (fr) 2014-08-14

Similar Documents

Publication Publication Date Title
WO2014123930A3 (fr) Prévention et traitement de fibrose de tissu
IL276192B (en) Modified Aav and preparations, methods and uses for gene transfer to cells, organs and tissues
WO2015075557A3 (fr) Compositions c/ebp alpha et méthodes d&#39;utilisation
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
WO2014108571A3 (fr) Médicament contre le cancer et utilisations
EP3233493A4 (fr) Bio-encre nanofibrillaire de cellulose pour bio-impression 3d pour des applications de culture de cellules, ingénierie tissulaire et médecine régénérative
EP2818543A4 (fr) Bacille, hyaluronidase et leurs applications
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2013170068A3 (fr) Modulateurs du transport nucléaire et leurs utilisations
WO2012129084A3 (fr) Inhibiteurs de la glucosylcéramide synthase
WO2012047733A3 (fr) Traitement de l&#39;acné par le biais de milieux conditionnés
WO2015069697A3 (fr) Polythérapie
WO2012116010A3 (fr) Inhibiteurs de la tolérance aux antibiotiques
EP3238745A4 (fr) Agent inducteur de mort cellulaire, agent cytostatique, et composition pharmaceutique pour le traitement de maladies provoquées par une croissance cellulaire anormale
UY32444A (es) Composiciones y procedimientos para terapia extendida con aminopiridinas
WO2012024260A3 (fr) Administration intranasale d&#39;agents thérapeutiques augmentant la perméabilité cellulaire
WO2012135619A3 (fr) Compositions pharmaceutiques intranasales de benzodiazépine
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
WO2013117744A3 (fr) Méthodes de traitement de la fibrose
EP2818172A4 (fr) Agent tlr4, agent d&#39;homéostasie tissulaire, activateur du facteur de croissance des hépatocytes, agent de réparation tissulaire, et activateur de sirtuine ayant des fragments d&#39;acide hyaluronique en tant que principes actifs associés
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
WO2013028904A3 (fr) Compositions de comblement dermique contenant des antioxydants
EP3002011A4 (fr) Composition de cellules souches pour administration veineuse
WO2011014520A3 (fr) Composés et compositions pouvant servir de modulateurs de l&#39;activité du gpr119
AR094224A1 (es) Composicion farmaceutica en forma de una suspension oral

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14749444

Country of ref document: EP

Kind code of ref document: A2